Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 6 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)RecruitingNCT07193550Phase 2
- Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingNCT07193394Phase 2
- Anlotinib and Benmelstobart in DTCNot yet recruitingNCT07193186Phase 2
- Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNot yet recruitingNCT07193160Phase 2
- Adebrelimab + Apatinib in Advanced HCC Post-Systemic TherapyNot yet recruitingNCT07192848Phase 2
- A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）RecruitingNCT07191431Not applicable
- A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseRecruitingNCT07190196Phase 3
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07189065Phase 2
- Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenRecruitingNCT07188311Not applicable
- Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyRecruitingNCT07187869Phase 1
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Phase 3
- Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior TherapyNot yet recruitingNCT07185945Phase 2
- Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLRecruitingNCT07185373Phase 2/3
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Phase 3
- Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKIRecruitingNCT07181499Phase 2
- Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast CancerRecruitingNCT07180082Phase 2
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2
- Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)Not yet recruitingNCT07178912Phase 2
- Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS PatientsNot yet recruitingNCT07174492Phase 3
- Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07172412Phase 2
- Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCCRecruitingNCT07172386Phase 2
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorRecruitingNCT07171203Phase 1
- Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial CancerNot yet recruitingNCT07170982Phase 2
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT07169994Phase 1/2
- Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingNCT07169565Phase 1
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingNCT07165418Phase 3
- Nintedanib for Improving Reproductive Outcomes in AdenomyosisNot yet recruitingNCT07162961Phase 3
- A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy ParticipantsRecruitingNCT07162116Phase 1
- A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)RecruitingNCT07161258Phase 2
- Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TBNot yet recruitingNCT07160361Phase 4
- Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2
- Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaNot yet recruitingNCT07159191Phase 2
- A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.Not yet recruitingNCT07156643Phase 2
- Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07156019Phase 2
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07155187Phase 2/3
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)RecruitingNCT07154706Phase 3
- JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.Not yet recruitingNCT07154368Phase 3
- A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)RecruitingNCT07154264Phase 2
- Vebreltinib for Advanced or Metastatic CCSRecruitingNCT07153887Phase 2
- Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung CancerNot yet recruitingNCT07153770Phase 2
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerRecruitingNCT07153055Phase 1/2
- T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisRecruitingNCT07152782Phase 2
- Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Phase 3
- Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination TherapyNot yet recruitingNCT07151326Phase 2
- Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal CancerNot yet recruitingNCT07150403Phase 2
- Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled StudyNot yet recruitingNCT07149467Phase 3
- Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesRecruitingNCT07149090Phase 1/2
- Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsRecruitingNCT07148947Phase 2
- Feasibility Study for Repurposing RET InhibitorsNot yet recruitingNCT07146893Early Phase 1
- A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical CancerNot yet recruitingNCT07143292Phase 2
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07140016Phase 1
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)RecruitingNCT07139873Phase 3
- Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast CancerNot yet recruitingNCT07139470Phase 1/2
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
- A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host DiseaseRecruitingNCT07138196Phase 1
- Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in ChildrenNot yet recruitingNCT07137884Phase 2
- Asciminib in HER2+ Breast Cancer Brain MetastasesRecruitingNCT07136428Phase 1/2
- Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia AreataRecruitingNCT07133308Phase 3
- SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast CancerNot yet recruitingNCT07132242Phase 2
- Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen PlanusRecruitingNCT07131813Phase 4
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07131501Phase 2
- MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
- A Study of Aumolertinib in European Participants With Non-Small Cell Lung CancerRecruitingNCT07130916Phase 1
- Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal CancerRecruitingNCT07130903Phase 2
- Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingNCT07128381Phase 1/2
- A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionRecruitingNCT07128199Phase 3
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaRecruitingNCT07126158Phase 2
- Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT07124858Not applicable
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingNCT07123090Phase 2
- Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07122609Phase 2
- Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon MutationsRecruitingNCT07117890Phase 2
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)RecruitingNCT07116967Phase 3
- NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's LymphomaRecruitingNCT07114367Phase 1
- Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLCRecruitingNCT07110103Phase 2
- A Study of Zasocitinib in Adults With Nonsegmental VitiligoRecruitingNCT07108283Phase 2
- HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)RecruitingNCT07105748Phase 2
- Momelotinib During and After HCT in MyelofibrosisRecruitingNCT07104799Phase 1
- IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT07104032Phase 3
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized TrialRecruitingNCT07101588Phase 4
- Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell CarcinomaRecruitingNCT07097935Phase 1/2
- Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsRecruitingNCT07096609Phase 1/2
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT07093710Phase 1/2
- Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)RecruitingNCT07092514Phase 2
- Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal MetastasesRecruitingNCT07092202Phase 4
- ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG TrialRecruitingNCT07089641Phase 1
- A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaRecruitingNCT07086976Phase 3
- Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07086456Phase 2
- Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman DiseaseRecruitingNCT07085039Phase 2
- Lorlatinib in ROS1+ NSCLC With Brain MetastasisNot yet recruitingNCT07083687Phase 2
- A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)RecruitingNCT07082868Phase 1
- Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment InterruptionNot yet recruitingNCT07081763Phase 2
- Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.Not yet recruitingNCT07081607Phase 2
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingNCT07079475Phase 1/2
- Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line TreatmentNot yet recruitingNCT07078305Phase 2
- Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver ResectionNot yet recruitingNCT07077798Not applicable
- Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical StudyNot yet recruitingNCT07075250Phase 4
- Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.RecruitingNCT07074496Early Phase 1
- Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]RecruitingNCT07071961Phase 2
- Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaRecruitingNCT07071155Early Phase 1
- Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07070700Phase 2